Vectans Pharma is delighted to collaborate with the Menarini group and Berlin Chemie for the commercialization of Sitavig® in Italy and Austria.
Season's greetings
Vectans Pharma wishes you a happy and healthy New Year!
Vectans Pharma participated in a symposium about new treatments in Oropharyngeal Candidiasis
Dr Pierre Attali, our Chief Medical Officer, represented Vectans Pharma at the symposium organized by our Japanese partner Sosei Heptares about new treatments.
CPhI Worldwide 2022 in Frankfurt, November 1st-3rd
Vectans Pharma will be present at the CPhI worldwide in Frankfurt from November 01 to 03, 2022.
Exclusif agreement with Berlin Chemie for Sitavig®
Vectans Pharma is delighted to collaborate withBerlin Chemie expanding the international scope of Sitavig® to 30 additional countries.
Welcome to Medine Kockan, our new talent!
We are thrilled to welcome Medine Kockan as our new intern in Marketing and Strategic Innovation!
She will contribute to the many projects of our team. We are excited for her to participate in our continued growth!
Navamedic ASA : exclusive agreement for Sitavig®
Vectans Pharma will be present at the CPhI worldwide in Milan from November 9 to 11, 2021.
OTC switch approval for Sitavig® 50 mg in France
Vectans pharma is proud to announce that its one-per-episode Lauriad® aciclovir treatment tablet for herpes labialis, Sitavig® 50mg, has received the approbation of the ANSM for OTC commercialization in France. Issued from Lauriad technology, SITAVIG ensures an optimum and efficient localized concentration of acyclovir directly at the disease site.
A big step for Vectans , but also for the many patients in France prone to recurrent
Lauriad® technology in pictures
Because changing the way medicines are delivered can improve patient’s life drastically. With Lauriad® we are committed to optimizing the existing therapeutic offer, bringing out new « best-in-disease » drugs.
Copyright © VECTANS PHARMA